← Back to Search

PrEP messages for HIV (Human Immunodeficiency Virus)

N/A

Waitlist Available

Led By Frederick Altice, M.D., M.A.

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24-weeks

Awards & highlights

Study Summary

This trial will study whether or not a social media intervention can increase the use of PrEP by young men who have sex with men in the New Haven area.

Eligible Conditions

HIV (Human Immunodeficiency Virus)
Men
Pre-Exposure Prophylaxis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24-weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24-weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24-weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

PrEP uptake

Secondary outcome measures

HIV testing

PrEP knowledge

PrEP stigma

+4 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: PrEP MessagesExperimental Treatment1 Intervention

The peer leaders and the study staff will post PrEP related health messages

Group II: Health messagesActive Control1 Intervention

The peer leaders and study staff will post general health messages that are not related to sexual health.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PrEP messages

2018

N/A

~230

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor

1,848 Previous Clinical Trials

2,737,591 Total Patients Enrolled

Substance Abuse and Mental Health Services Administration (SAMHSA)FED

30 Previous Clinical Trials

23,081 Total Patients Enrolled

Frederick Altice, M.D., M.A.Principal InvestigatorYale University

2 Previous Clinical Trials

1,528 Total Patients Enrolled

Media Library

PrEP messages Clinical Trial Eligibility Overview. Trial Name: NCT04417946 — N/A

HIV (Human Immunodeficiency Virus) Research Study Groups: PrEP Messages, Health messages

HIV (Human Immunodeficiency Virus) Clinical Trial 2023: PrEP messages Highlights & Side Effects. Trial Name: NCT04417946 — N/A

PrEP messages 2023 Treatment Timeline for Medical Study. Trial Name: NCT04417946 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is eligibility for this trial limited to those over eighteen years of age?

"This medical trial seeks participants who are between 18 and 29 years old."

Answered by AI

What are the qualifications for participation in this clinical experiment?

"This study seeks 325 volunteers between adolescence and 29 years of age with men, who identify as either gay or bisexual. Additionally, candidates must be biologically male or transgender man to qualify for the trial."

Answered by AI

How many participants are being enrolled in this experiment?

"Affirmative. According to clinicaltrials.gov, this research project is actively seeking participants and was initially posted on June 5th 2018. Moreover, 325 people are needed from 2 trial sites in order for the study to move forward."

Answered by AI

Is there currently an opportunity for participants to enroll in this study?

"Affirmative, the information posted on clinicaltrials.gov clearly states that this medical study is actively recruiting participants. Initially uploaded to the platform on June 5th 2018 and more recently updated on May 19th 2022, it seeks 325 patients from two distinct sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Peer-led Social Media Intervention to Prevent HIV Among Young Men Who Have Sex With Men (YMSM)

2018. "Peer-led Social Media Intervention to Prevent HIV Among Young Men Who Have Sex With Men (YMSM)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04417946.